Agitation-Induced Aggregation of Lysine- and Interchain Cysteine-Linked Antibody-Drug Conjugates
- J Pharm Sci. 2023 Dec 7:S0022-3549(23)00511-7. doi: 10.1016/j.xphs.2023.12.003.
- 1. Friedrich-Alexander University (FAU) ErlangenNürnberg, Department of Pharmaceutics, Freeze Drying Focus Group (FDFG), Cauerstraße 4, 91058 Erlangen, Germany; Merck KGaA, Global CMC Development, Frankfurter Straße 250, 64293 Darmstadt, Germany.
- 2. Merck KGaA, Global CMC Development, Frankfurter Straße 250, 64293 Darmstadt, Germany.
- 3. Friedrich-Alexander University (FAU) ErlangenNürnberg, Department of Pharmaceutics, Freeze Drying Focus Group (FDFG), Cauerstraße 4, 91058 Erlangen, Germany; GILYOS GmbH, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany. Electronic address: [email protected].
Drug conjugation to an antibody can affect its stability, which depends on factors such as the conjugation technique used, drug-linker properties, and stress encountered. This study focused on the effects of agitation stress on the physical stability of two lysine (ADC-K) and two interchain cysteine (ADC-C) conjugates of an IgG1 monoclonal antibody (mAb) linked to either ∼4 MMAE or DM1 payloads. During agitation, all antibody-drug conjugates (ADCs) exhibited higher aggregation than the mAb, which was dependent on the conjugation technique (aggregation of ADC-Ks > ADC-Cs) and drug-linker (aggregation of ADCs with MMAE > ADCs with DM1). The aggregation propensities correlated well with higher self-interaction, hydrophobicity, and surface activity of ADCs relative to the mAb. The intermediate reduced mAb (mAb-SH) showed even higher aggregation than the final product ADC-Cs. However, blocking mAb-SH's free thiols with N-ethylmaleimide (NEM) strongly reduced its aggregation, suggesting that free thiols should be minimized in cysteine ADCs. Further, this study demonstrates that a low-volume surface tension method can be used for estimating agitation-induced aggregation of ADCs in early development phases. Identifying liabilities to agitation stress and their relationship to biophysical properties may help optimize ADC stability.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
target: Drug-Linker Conjugates for ADCResearch Areas: Cancer
-
target: Drug-Linker Conjugates for ADCResearch Areas: Cancer